Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Applying the essential medicines concept to US preferred drug lists.

Millar TP, Wong S, Odierna DH, Bero LA.

Am J Public Health. 2011 Aug;101(8):1444-8. doi: 10.2105/AJPH.2010.300054. Epub 2011 Jun 16.

2.

How similar are states' Medicaid preferred drug lists?

Ketcham JD, Ngai JK.

Am J Manag Care. 2008 Nov;14(11 Suppl):SP46-52.

3.

Which physicians are affected most by Medicaid preferred drug lists for statins and antihypertensives?

Ketcham JD, Epstein AJ.

Pharmacoeconomics. 2006;24 Suppl 3:27-40.

PMID:
17266386
4.

Medicaid preferred drug lists' costs to physicians.

Ketcham JD, Epstein AJ.

Med Care. 2008 Jan;46(1):9-16.

PMID:
18162850
5.

Preferred drug lists: potential impact on healthcare economics.

Ovsag K, Hydery S, Mousa SA.

Vasc Health Risk Manag. 2008;4(2):403-13. Review.

6.

Essential psychiatric medicines: wrong selection, high consumption and social problems.

Fulone I, Barberato-Filho S, dos Santos MF, Rossi Cde L, Guyatt G, Lopes LC.

BMC Public Health. 2016 Jan 20;16:52. doi: 10.1186/s12889-015-2589-1.

7.

Patent and exclusivity status of essential medicines for non-communicable disease.

Mackey TK, Liang BA.

PLoS One. 2012;7(11):e51022. doi: 10.1371/journal.pone.0051022. Epub 2012 Nov 30.

8.

Essential medicines for cancer: WHO recommendations and national priorities.

Robertson J, Barr R, Shulman LN, Forte GB, Magrini N.

Bull World Health Organ. 2016 Oct 1;94(10):735-742. Epub 2016 Jul 5.

9.

Can the selection and use of essential medicines decrease inappropriate drug use?

Reidenberg MM.

Clin Pharmacol Ther. 2009 Jun;85(6):581-3. doi: 10.1038/clpt.2009.10.

PMID:
19451911
10.

The Selection and Use of Essential Medicines.

[No authors listed]

World Health Organ Tech Rep Ser. 2015;(994):vii-xv, 1-546.

PMID:
27183787
11.
12.

The selection and use of essential medicines.

World Health Organization.

World Health Organ Tech Rep Ser. 2011;(965):i-xiv, 1-249.

PMID:
22891532
13.

National Essential Medicines List and policy practice: a case study of China's health care reform.

Tian X, Song Y, Zhang X.

BMC Health Serv Res. 2012 Nov 14;12:401. doi: 10.1186/1472-6963-12-401.

14.
15.

The selection and use of essential medicines.

WHO Expert Committee.

World Health Organ Tech Rep Ser. 2008;(950):backcover, vii-174.

PMID:
18754303
16.
17.

The effect of access restrictions on the vintage of drugs used by Medicaid enrollees.

Lichtenberg FR.

Am J Manag Care. 2005 Jan;11 Spec No:SP7-13. Review.

18.

Availability of pediatric-evaluated formulations in Serbia.

Božić B, Stupar S, Stupar D, Babić U, Bajčetić M.

Indian J Pharmacol. 2017 Mar-Apr;49(2):189-193. doi: 10.4103/ijp.IJP_66_16.

19.

Using the WHO essential medicines list to assess the appropriateness of insurance coverage decisions: a case study of the Croatian national medicine reimbursement list.

Jeličić Kadić A, Žanić M, Škaričić N, Marušić A.

PLoS One. 2014 Oct 22;9(10):e111474. doi: 10.1371/journal.pone.0111474. eCollection 2014.

20.

The selection and use of essential medicines.

WHO Expert Committee.

World Health Organ Tech Rep Ser. 2007;(946):1-162, back cover.

PMID:
18309920

Supplemental Content

Support Center